Moreover, Gal1 downregulation in lung and ovarian cancer cells by shGal1 and siGal1, respectively, have shown to significantly decrease viability after cisplatin treatment in comparison to control transfected cells, suggesting that Gal1 depletion enhances sensitivity to cisplatin [108,109]. Here, LGALS1 is linked to ovarian cancer.